Co-Authors
This is a "connection" page, showing publications co-authored by Marek Jutel and Ioana Agache.
Connection Strength
2.752
-
Real-life impact of COVID-19 pandemic lockdown on the management of pediatric and adult asthma: A survey by the EAACI Asthma Section. Allergy. 2021 09; 76(9):2776-2784.
Score: 0.235
-
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. Allergy. 2021 03; 76(3):648-676.
Score: 0.233
-
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy. 2021 03; 76(3):689-697.
Score: 0.226
-
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select. 2020; 4:53-68.
Score: 0.225
-
Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document. Allergy. 2019 03; 74(3):449-463.
Score: 0.200
-
International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016 Feb; 137(2):358-68.
Score: 0.164
-
COVID-19 vaccines-The way forward. Allergy. 2022 01; 77(1):15-16.
Score: 0.062
-
Management of anaphylaxis due to COVID-19 vaccines in the elderly. Allergy. 2021 10; 76(10):2952-2964.
Score: 0.061
-
COVID-19 pandemic and allergen immunotherapy-an EAACI survey. Allergy. 2021 11; 76(11):3504-3516.
Score: 0.060
-
ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper. Allergy. 2021 06; 76(6):1624-1628.
Score: 0.059
-
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021 06; 76(6):1629-1639.
Score: 0.059
-
Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2 LEN consensus. Allergy. 2021 08; 76(8):2354-2366.
Score: 0.059
-
Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper. Allergy. 2021 03; 76(3):677-688.
Score: 0.058
-
Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. Int Arch Allergy Immunol. 2021; 182(4):324-338.
Score: 0.058
-
Spices to Control COVID-19 Symptoms: Yes, but Not Only…. Int Arch Allergy Immunol. 2021; 182(6):489-495.
Score: 0.057
-
Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. Allergy. 2020 11; 75(11):2764-2774.
Score: 0.057
-
Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020 10; 75(10):2445-2476.
Score: 0.057
-
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy. 2020 10; 75(10):2440-2444.
Score: 0.057
-
A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy. 2020 10; 75(10):2503-2541.
Score: 0.056
-
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy. 2020 07; 75(7):1546-1554.
Score: 0.056
-
Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019. Allergy. 2020 04; 75(4):936-940.
Score: 0.053
-
The urgent need for a harmonized severity scoring system for acute allergic reactions. Allergy. 2018 09; 73(9):1792-1800.
Score: 0.048
-
EAACI guidelines on allergen immunotherapy: Executive statement. Allergy. 2018 04; 73(4):739-743.
Score: 0.048
-
Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project. Allergy. 2018 04; 73(4):816-826.
Score: 0.047
-
Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy. Allergy. 2018 04; 73(4):827-836.
Score: 0.047
-
EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018 04; 73(4):744-764.
Score: 0.047
-
EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018 04; 73(4):799-815.
Score: 0.047
-
EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018 04; 73(4):765-798.
Score: 0.046
-
EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017 Dec; 28(8):728-745.
Score: 0.046
-
Erratum to: Allergen immunotherapy for allergic asthma: protocol for a systematic review. Clin Transl Allergy. 2017; 7:32.
Score: 0.046
-
Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy. 2018 Jan; 73(1):64-76.
Score: 0.046
-
Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. Clin Transl Allergy. 2017; 7:25.
Score: 0.045
-
Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017 Dec; 72(12):1825-1848.
Score: 0.045
-
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016; 6:47.
Score: 0.044